Rallybio Corp - ESG Rating & Company Profile powered by AI
If you are employed by Rallybio Corp and you would like to licence your Sustainability aseessment, please contact us. This SDG rating for Rallybio Corp represents its transparency towards the UN SDGs. Alternative companies in the scoring peer group for Rallybio Corp are shown.
Rallybio Corp in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.5; made up of an environmental score of 4.5, social score of 6.0 and governance score of 6.0.
8.5
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 4 | Johnson & Johnson | 8.6 | High |
| 4 | Sanofi SA | 8.6 | High |
| 8 | Rallybio Corp | 8.5 | High |
| 8 | Jazz Pharmaceuticals PLC | 8.5 | High |
| 8 | Pfizer Inc | 8.5 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Rallybio Corp have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Rallybio Corp disclose current and historical energy intensity?
Sign up for free to unlockDoes Rallybio Corp report the average age of the workforce?
Sign up for free to unlockDoes Rallybio Corp reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Rallybio Corp disclose its ethnicity pay gap?
Sign up for free to unlockDoes Rallybio Corp disclose cybersecurity risks?
Sign up for free to unlockDoes Rallybio Corp offer flexible work?
Sign up for free to unlockDoes Rallybio Corp have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Rallybio Corp disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Rallybio Corp conduct supply chain audits?
Sign up for free to unlockDoes Rallybio Corp disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Rallybio Corp conduct 360 degree staff reviews?
Sign up for free to unlockDoes Rallybio Corp disclose the individual responsible for D&I?
Sign up for free to unlockDoes Rallybio Corp disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Rallybio Corp disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Rallybio Corp disclose water use targets?
Sign up for free to unlockDoes Rallybio Corp have careers partnerships with academic institutions?
Sign up for free to unlockDid Rallybio Corp have a product recall in the last two years?
Sign up for free to unlockDoes Rallybio Corp disclose incidents of discrimination?
Sign up for free to unlockDoes Rallybio Corp allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Rallybio Corp issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Rallybio Corp disclose parental leave metrics?
Sign up for free to unlockDoes Rallybio Corp disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Rallybio Corp disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Rallybio Corp disclose the pay ratio of women to men?
Sign up for free to unlockDoes Rallybio Corp support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Rallybio Corp disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Rallybio Corp reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Rallybio Corp involved in embryonic stem cell research?
Sign up for free to unlockDoes Rallybio Corp disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Rallybio Corp disclose its waste policy?
Sign up for free to unlockDoes Rallybio Corp report according to TCFD requirements?
Sign up for free to unlockDoes Rallybio Corp disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Rallybio Corp disclose energy use targets?
Sign up for free to unlockDoes Rallybio Corp disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Rallybio Corp have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Rallybio Corp
These potential risks are based on the size, segment and geographies of the company.
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.